TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21890090

Group type: EXPERIMENTAL
Intervention: Presence of ventricular tachycardia (VT) alone
Number of subjects: 6355

Group type: EXPERIMENTAL
Intervention: Presence of ischemia alone
Number of subjects: 6355

Group type: EXPERIMENTAL
Intervention: Combination of ischemia and VT
Number of subjects: 6355

Group type: EXPERIMENTAL
Intervention: Addition of arrhythmia and ischemia to clinical model
Number of subjects: 6355

Group type: EXPERIMENTAL
Intervention: Patients with both ischemia and VT
Number of subjects: 6355
Study: 19218804

Group type: EXPERIMENTAL
Intervention: Cardiac troponin T (cTnT) measurement on the third morning after onset of STEMI
Number of subjects: 103
Study: 15927929

Group type: EXPERIMENTAL
Intervention: Tomatoes cooked with olive oil (25 ml); 470 g per meal for 5 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tomatoes cooked without olive oil; 470 g per meal for 5 days
Number of subjects: 23
Study: 12052481

Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10333123

Group type: EXPERIMENTAL
Intervention: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus vaccine
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Hiberix, ActHib, Pedvax, HibTITER (Hib conjugate vaccines)
Number of subjects: 549
Study: 8949976

Group type: EXPERIMENTAL
Intervention: Long-term therapy to improve glucose control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved control of hypertension
Number of subjects: 0
Study: 1754753

Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg twice daily for 7 days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Pivampicillin 700 mg twice daily for 7 days
Number of subjects: 104
Study: 7169286

Group type: EXPERIMENTAL
Intervention: Food additives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31222796

Group type: EXPERIMENTAL
Intervention: Chlorzoxazone 500 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorzoxazone microdose (0.05-500 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorzoxazone microdose (≥50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorzoxazone microdose
Number of subjects: 12
Study: 28978240

Group type: EXPERIMENTAL
Intervention: Trans-abdominal guided IUD insertion
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional IUD insertion
Number of subjects: 102
Study: 27539026

Group type: EXPERIMENTAL
Intervention: Reading on a self-luminous tablet
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reading a physical book
Number of subjects: 14
Study: 24773254

Group type: EXPERIMENTAL
Intervention: HIIT (10 × 1 min at approximately 90% peak heart rate (HRpeak) with 1‐min recovery periods)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CMI (30 min at approximately 65% HRpeak)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CMI
Number of subjects: 10
Study: 23015562

Group type: EXPERIMENTAL
Intervention: Mobile-bearing (MB) total knee replacement
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fixed-bearing (FB) total knee replacement
Number of subjects: 42
Study: 19320869

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHP)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Artesunate-amodiaquine (AAQ)
Number of subjects: 116
Study: 17650790

Group type: EXPERIMENTAL
Intervention: Guben Yiliu II (GY II) combined with arterial perfusion with chemotherapeutic agent
Number of subjects: 65

Group type: COMPARATOR
Intervention: Chemotherapeutic agent alone
Number of subjects: 65
Study: 14738236

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure for 2 hours at ambient levels (PM10 108 microg x m(‐3))
Number of subjects: 0
Study: 12204321

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 9695720

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole once daily for 4 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 10
Study: 7866915

Group type: EXPERIMENTAL
Intervention: 1 g of oral calcium
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 200 IU of intranasal calcitonin
Number of subjects: 9

Group type: COMPARATOR
Intervention: No treatment (control session)
Number of subjects: 9
Study: 2547245

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin for three months in addition to conventional local therapy (N=18)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional local therapy (Control group, N=8)
Number of subjects: 26
Study: 577494

Group type: EXPERIMENTAL
Intervention: Communication training using written words (based on Terrace's errorless discrimination model and Premack's language training)
Number of subjects: 3
Study: 31549413

Group type: EXPERIMENTAL
Intervention: Care bundle group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Emergency department compliance
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Anaesthetic department compliance
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Orthogeriatrics compliance
Number of subjects: 300
Study: 31514425

Group type: EXPERIMENTAL
Intervention: aL procedure
Number of subjects: 44
Study: 28053158

Group type: EXPERIMENTAL
Intervention: Bioengineered bilayered living cellular construct (BLCC) skin substitute together with standard of care (compression therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (compression therapy)
Number of subjects: 0
Study: 25727741

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 22)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 41
Study: 23763822

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 72

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 72
Study: 21457668

Group type: EXPERIMENTAL
Intervention: Oral alpha-lipoic acid (ALA) 1200 mg/day for 8 weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo 1200 mg/day for 8 weeks
Number of subjects: 103
Study: 18222683

Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler
Number of subjects: 77

Group type: COMPARATOR
Intervention: Formoterol pMDI+S (control)
Number of subjects: 77
Study: 16517331

Group type: EXPERIMENTAL
Intervention: Group P - preoperative placebo tablet, propofol induction, propofol-air/O2 maintenance
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Group I + O - preoperative 8-mg ondansetron tablet, thiopental induction, isoflurane-N2O maintenance
Number of subjects: 150

Group type: COMPARATOR
Intervention: Group I (control) - preoperative placebo tablet, thiopental induction, isoflurane-N2O maintenance
Number of subjects: 150
Study: 12802713

Group type: EXPERIMENTAL
Intervention: High risk of perinatal infection (n=8)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Healthy newborns (n=59)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Low risk of perinatal infection (n=18)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: High risk of perinatal infection (n=20) in 37 to 72-hour subgroup
Number of subjects: 166

Group type: COMPARATOR
Intervention: Healthy newborns (n=49) in 37 to 72-hour subgroup
Number of subjects: 166

Group type: COMPARATOR
Intervention: Low risk of perinatal infection (n=12) in 37 to 72-hour subgroup
Number of subjects: 166
Study: 11019880

Group type: EXPERIMENTAL
Intervention: Tracey Technology wavefront device
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional videokeratoscopes
Number of subjects: 9
Study: 8888927

Group type: EXPERIMENTAL
Intervention: Early physiotherapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard treatment (delaying physiotherapy until abnormal physical signs became apparent)
Number of subjects: 105
Study: 1507376

Group type: EXPERIMENTAL
Intervention: Computer-based interview
Number of subjects: 294

Group type: COMPARATOR
Intervention: Standard Red Cross procedure
Number of subjects: 294
Study: 6367929

Group type: EXPERIMENTAL
Intervention: Alza T IPCS 52
Number of subjects: 5542

Group type: COMPARATOR
Intervention: TCu22OC
Number of subjects: 5542

Group type: COMPARATOR
Intervention: Multiload 250
Number of subjects: 5542
Study: 30896976

Group type: EXPERIMENTAL
Intervention: Standard IKDC‐SKF
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Involved R/L IKDC‐SKF
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: R/L IKDC‐SKF
Number of subjects: 100
Study: 29167485

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 0
Study: 27485060

Group type: EXPERIMENTAL
Intervention: Rowachol 100 mg orally three times daily for 3 months after surgery
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 24976083

Group type: EXPERIMENTAL
Intervention: Non-transfer patients
Number of subjects: 9204

Group type: COMPARATOR
Intervention: Transferred patients
Number of subjects: 9204
Study: 21680781

Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg once a day for 13 days
Number of subjects: 18
Study: 19301734

Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost (10 Gy/25F)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sequential boost (15 Gy/5F)
Number of subjects: 60
Study: 17461530

Group type: EXPERIMENTAL
Intervention: 40mL of 300mg ropivacaine with 1:200,000 epinephrine and 5mg morphine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 40mL of 300mg ropivacaine with epinephrine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 50mL normal saline (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 15200445

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg administered 2 hours before hemodialysis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg administered 2 hours after hemodialysis
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no sildenafil)
Number of subjects: 15
Study: 12473004

Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg bid or 100 mg bid for 12, 16, or 24 weeks
Number of subjects: 1751

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1751
Study: 11440349

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB), dosage up to 64 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 9402169

Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2), Epirubicin (70 mg/m2), Paclitaxel (175 mg/m2 over three hours)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cisplatin, Epirubicin, and Paclitaxel (CEP) regimen
Number of subjects: 49
Study: 8500917

Group type: EXPERIMENTAL
Intervention: ITF 282 (60 mg iron once daily for children ≤40 kg; twice daily for children >40 kg)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Ferrous polystyrene sulphonate (52.5 mg iron once daily for children ≤40 kg; twice daily for children >40 kg)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: ITF 282
Number of subjects: 502

Group type: COMPARATOR
Intervention: Ferrous polystyrene sulphonate
Number of subjects: 502
Study: 3319629

Group type: EXPERIMENTAL
Intervention: Exercise training plus individual relaxation and breathing therapy (treatment A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Exercise training only (treatment B)
Number of subjects: 90
Study: 29196816

Group type: EXPERIMENTAL
Intervention: Continuing nursing care
Number of subjects: 74

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 74
Study: 28090293

Group type: EXPERIMENTAL
Intervention: Oral treprostinil (up-titrated from 0.25 mg twice daily)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 24128818

Group type: EXPERIMENTAL
Intervention: Internet-based program ('ESS-KIMO') consisting of six online MET sessions
Number of subjects: 212

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 212
Study: 22084312

Group type: EXPERIMENTAL
Intervention: Carriers of the -1377A variant of the CD95 gene
Number of subjects: 231
Study: 20450357

Group type: EXPERIMENTAL
Intervention: mod SLA implants
Number of subjects: 39

Group type: COMPARATOR
Intervention: historic control group with SLA surface
Number of subjects: 39
Study: 16189077

Group type: EXPERIMENTAL
Intervention: Single 2.0-g oral dose of azithromycin microspheres (n = 213)
Number of subjects: 427

Group type: COMPARATOR
Intervention: 7-day regimen of levofloxacin (500 mg/day) (n = 214)
Number of subjects: 427
Study: 12549813

Group type: EXPERIMENTAL
Intervention: In-person counseling
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: In-person counseling and physician's letter intervention
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Telephone contact and physician's letter combination
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Physician's letter
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: In-person counseling and physician's letter combination
Number of subjects: 652

Group type: COMPARATOR
Intervention: All 5 interventions
Number of subjects: 652
Study: 10381107

Group type: EXPERIMENTAL
Intervention: Calcium mupirocin ointment
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 8873694

Group type: EXPERIMENTAL
Intervention: Isosorbide (20 mg by mouth t.i.d.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nicardipine (20 mg by mouth t.i.d.)
Number of subjects: 20
Study: 1998848

Group type: EXPERIMENTAL
Intervention: 50 mg stanozolol intramuscularly 24 hours before operation, followed by 5 mg stanozolol orally twice daily for 6 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo intramuscularly 24 hours before operation, followed by placebo orally twice daily for 6 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Stanozolol
Number of subjects: 27
Study: 28726810

Group type: EXPERIMENTAL
Intervention: Telephone disclosure of genetic test results
Number of subjects: 257

Group type: COMPARATOR
Intervention: In-person disclosure of genetic test results
Number of subjects: 257
Study: 27316679

Group type: EXPERIMENTAL
Intervention: Yirui capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24733515

Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention including motivational interviewing, medication, and cognitive behavioral therapy targeting PTSD and depressive symptoms.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 120
Study: 22214752

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 20463564

Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Corticosteroid injection (methylprednisolone)
Number of subjects: 60
Study: 17522603

Group type: EXPERIMENTAL
Intervention: High calcium-high vitamin D breakfast (HCB)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low calcium-low vitamin D breakfast
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both lunches (after HCB and low calcium-low vitamin D breakfast)
Number of subjects: 8
Study: 16782910

Group type: EXPERIMENTAL
Intervention: PCV chemotherapy plus radiotherapy (RT), n = 147
Number of subjects: 289

Group type: COMPARATOR
Intervention: RT alone, n = 142
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: PCV plus RT
Number of subjects: 289

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Patients with tumors lacking 1p and 19q
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Patients with tumors not lacking 1p and 19q
Number of subjects: 289
Study: 14567804

Group type: EXPERIMENTAL
Intervention: Triptorelin depot 11.25 mg 3 months before surgery (group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 62
Study: 10751862

Group type: EXPERIMENTAL
Intervention: Mitoxantrone and prednisone
Number of subjects: 133
Study: 9096431

Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg/day) for 1 month
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cirrhosis Child A
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cirrhosis Child C
Number of subjects: 32
Study: 8472118

Group type: EXPERIMENTAL
Intervention: Fractionated radiotherapy
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: T3 tumours
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: T2 tumours
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: T1 tumours
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Time component
Number of subjects: 1345
Study: 2422744

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29850858

Group type: EXPERIMENTAL
Intervention: General domain (n = 58)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Health domain (n = 60)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Behavioral domain (n = 56)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: TACT domain (n = 60)
Number of subjects: 234
Study: 30246666

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 1120
Study: 26508298

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 µg/day)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 159
Study: 25360652

Group type: EXPERIMENTAL
Intervention: Ulinastatin (intravenous)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (natural saline)
Number of subjects: 40
Study: 22119318

Group type: EXPERIMENTAL
Intervention: Placebo (CS less painful)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nocebo (CS more painful)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Informed control for placebo group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Informed control for nocebo group
Number of subjects: 48
Study: 19660461

Group type: EXPERIMENTAL
Intervention: Fasting and postprandial colonic tone and compliance in chronic constipation (NTC, STC, DD-normal, DD-slow)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Compliance in isolated STC and DD
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Principal components analysis of colonic motor parameters
Number of subjects: 146
Study: 18563972

Group type: EXPERIMENTAL
Intervention: music‐assisted progressive muscle relaxation (PMR) and imagery group (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: improvisation‐assisted desensitization group (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 30
Study: 16105282

Group type: EXPERIMENTAL
Intervention: Community-based distribution (CBD)
Number of subjects: 297
Study: 11961025

Group type: EXPERIMENTAL
Intervention: Stop CsA
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Stop Pred
Number of subjects: 212

Group type: COMPARATOR
Intervention: Continue triple drug therapy (Control)
Number of subjects: 212
Study: 10389350

Group type: EXPERIMENTAL
Intervention: Harmonic imaging
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fundamental imaging
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Second harmonic imaging
Number of subjects: 15
Study: 7553634

Group type: EXPERIMENTAL
Intervention: 2B1 at 1.0 mg/m2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2B1 at 2.5 mg/m2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2B1 at 5.0 mg/m2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2B1 (all doses)
Number of subjects: 15
Study: 2183632

Group type: EXPERIMENTAL
Intervention: Intravenous caffeine pretreatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electrical stimulus intensity dosing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Caffeine pretreatment
Number of subjects: 40
Study: 7392905

Group type: EXPERIMENTAL
Intervention: 15 mg of Dexedrine per 70 kg of body weight
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31372757

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100 mcg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 12
Study: 31029692

Group type: EXPERIMENTAL
Intervention: Transition Care Coordinator Care (TCC Care) - Full intervention (delivered in-hospital and by post-discharge phone call)
Number of subjects: 7038

Group type: EXPERIMENTAL
Intervention: Transition Care Coordinator Care (TCC Care) - Partial intervention (phone call only)
Number of subjects: 7038

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 7038
Study: 28815410

Group type: EXPERIMENTAL
Intervention: 4F-PCC (Beriplex®/Kcentra®)
Number of subjects: 11
Study: 25433202

Group type: EXPERIMENTAL
Intervention: IVUS-guided everolimus-eluting stent implantation
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Angiography-guided everolimus-eluting stent implantation
Number of subjects: 1400
Study: 23452523

Group type: EXPERIMENTAL
Intervention: Listening to personal choice of music for 30 minutes
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (rest in bed)
Number of subjects: 87
Study: 21747085

Group type: EXPERIMENTAL
Intervention: Edrecolomab (five infusions at 28-day intervals)
Number of subjects: 1738

Group type: COMPARATOR
Intervention: Observation without adjuvant therapy
Number of subjects: 1738
Study: 19267710

Group type: EXPERIMENTAL
Intervention: New insulin treatment (group III, n = 245)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Insulin before inclusion continued during the first year of follow up (group IV, n = 271)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Lowest quartile of body weight increase
Number of subjects: 865

Group type: COMPARATOR
Intervention: Each kilogram increase in weight
Number of subjects: 865

Group type: COMPARATOR
Intervention: Reinfarction incidence
Number of subjects: 865
Study: 17114657

Group type: EXPERIMENTAL
Intervention: Etoposide 100 mg/m2 on days 1-3 and cisplatin 80 mg/m2 on day 1 with concurrent twice-daily thoracic radiotherapy (TRT) (1.5 Gy per fraction, total dose of 45 Gy) followed by irinotecan 60 mg/m2 on days 1, 8, and 15 and cisplatin 60 mg/m2 on day 1 of a 4-week cycle
Number of subjects: 51